Publications

Huang, J., Liu, D., Wang, Y. et al. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut. (2021). http://dx.doi.org/10.1136/gutjnl-2020-321031

Yan, P., Su, Y., Shang, C. et al. The establishment of humanized IL-4/IL-4RA mouse model by gene editing and efficacy evaluation. Immunobiology. (2020). https://doi.org/10.1016/j.imbio.2020.151998

Liu, P., Pan, Z., Gu, C. et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. (2020). https://doi.org/10.3389/fimmu.2020.596908

Wu, F., Qiu, Y., Xu, Y. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. Cancer Immunol. Immunother. (2020). https://doi.org/10.1007/s00262-020-02640-6

Qi, X., Li, F., Wu, Y. et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. (2019). https://doi.org/10.1038/s41467-019-10088-1

Ma, L., Gai, J., Qiao, P. et al. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. Biochem. Biophys. Res. Commun. (2020). https://doi.org/10.1016/j.bbrc.2020.07.072

Wang Y, Lu JH, Wang F, Wang YN, He MM, Wu QN, Lu YX, Yu HE, Chen ZH, Zhao Q, Liu J, Chen YX, Wang DS, Sheng H, Liu ZX, Zeng ZL, Xu RH, Ju HQ. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. Cancer Lett. 2020 Mar 31;473:74-89. doi: 10.1016/j.canlet.2019.12.036. Epub 2020 Jan 2. PMID: 31904482.

Shi MM, Fan KM, Qiao YN, Xu JH, Qiu LJ, Li X, Liu Y, Qian ZQ, Wei CL, Han J, Fan J, Tian YF, Ren W, Liu ZQ. Hippocampal µ-opioid receptors on GABAergic neurons mediate stress-induced impairment of memory retrieval. Mol Psychiatry. 2020 May;25(5):977-992. doi: 10.1038/s41380-019-0435-z. Epub 2019 May 29. PMID: 31142818; PMCID: PMC7192851.

Wang, Y., Ni, H., Zhou, S. et al. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. (2021). https://doi.org/10.1007/s00262-020-02679-5

Xu, Z., Gao, J., Yao, J. et al. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody. FEBS Open Bio. (2021). https://doi.org/10.1002/2211-5463.13084